Brokerages forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will post earnings of ($0.49) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Crispr Therapeutics AG’s earnings. The firm is scheduled to report its next earnings report on Thursday, August 10th.
According to Zacks, analysts expect that Crispr Therapeutics AG will report full year earnings of ($2.24) per share for the current year. For the next year, analysts forecast that the firm will report earnings of ($2.45) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Crispr Therapeutics AG.
Crispr Therapeutics AG (NASDAQ:CRSP) last posted its quarterly earnings data on Thursday, May 11th. The company reported ($0.54) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.06. The business had revenue of $2.70 million for the quarter.
CRSP has been the subject of several recent research reports. Chardan Capital initiated coverage on shares of Crispr Therapeutics AG in a research report on Monday, March 27th. They set a “buy” rating and a $23.50 target price for the company. Piper Jaffray Companies set a $21.00 target price on shares of Crispr Therapeutics AG and gave the stock a “buy” rating in a research report on Thursday, February 16th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Crispr Therapeutics AG presently has an average rating of “Buy” and an average price target of $23.10.
Crispr Therapeutics AG (NASDAQ:CRSP) traded down 1.46% during trading on Tuesday, hitting $15.54. 60,004 shares of the stock were exchanged. The firm’s market cap is $618.65 million. Crispr Therapeutics AG has a 52 week low of $11.63 and a 52 week high of $25.00. The firm’s 50-day moving average is $17.78 and its 200 day moving average is $19.10.
In other Crispr Therapeutics AG news, insider Samarth Kulkarni sold 5,481 shares of the company’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $16.76, for a total value of $91,861.56. Following the completion of the sale, the insider now directly owns 137,322 shares of the company’s stock, valued at approximately $2,301,516.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Rodger Novak sold 50,000 shares of the company’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $16.26, for a total transaction of $813,000.00. Following the completion of the sale, the chief executive officer now directly owns 1,239,082 shares of the company’s stock, valued at $20,147,473.32. The disclosure for this sale can be found here. Insiders sold a total of 198,912 shares of company stock valued at $3,352,480 over the last ninety days.
A number of large investors have recently modified their holdings of CRSP. Clough Capital Partners L P purchased a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth about $16,676,000. Wellington Management Group LLP increased its stake in shares of Crispr Therapeutics AG by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares during the last quarter. Franklin Resources Inc. purchased a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth about $14,389,000. New Leaf Venture Partners L.L.C. purchased a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth about $11,882,000. Finally, Orbimed Advisors LLC purchased a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth about $7,541,000. 0.01% of the stock is owned by institutional investors and hedge funds.
About Crispr Therapeutics AG
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.